N
Natalie Artzi
Researcher at Massachusetts Institute of Technology
Publications - 89
Citations - 3381
Natalie Artzi is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Drug delivery & Medicine. The author has an hindex of 27, co-authored 82 publications receiving 2640 citations. Previous affiliations of Natalie Artzi include Broad Institute & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model
TL;DR: It is demonstrated that the combination of gene, drug and phototherapy delivered through a prophylactic hydrogel patch leads to complete tumour remission when applied to non-resected tumours and to the absence of tumour recurrence when applied following tumour resection.
Journal ArticleDOI
Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment
João Conde,Nuria Oliva,Mariana Atilano,Hyun Seok Song,Natalie Artzi,Natalie Artzi,Natalie Artzi +6 more
TL;DR: It is shown that a self-assembled dual-colour RNA-triple-helix structure comprising two miRNAs-a miR mimic (tumour suppressor miRNA) and an antagomiR (oncomiR inhibitor)- provides outstanding capability to synergistically abrogate tumours.
Journal ArticleDOI
In vivo and in vitro tracking of erosion in biodegradable materials using non-invasive fluorescence imaging
Natalie Artzi,Natalie Artzi,Nuria Oliva,Cristina Puron,Sagi Shitreet,Shay Artzi,Adriana bon Ramos,Adam Groothuis,G. Gary Sahagian,Elazer R. Edelman,Elazer R. Edelman +10 more
TL;DR: In this article, the authors track the hydrolytic and enzymatic erosion of model materials by non-invasive fluorescence imaging, which allows the prediction of in vivo erosion from in vitro data.
Journal ArticleDOI
Designing Hydrogels for On-Demand Therapy
TL;DR: It is demonstrated that the hydrogel platform developed in the lab, based on dendrimer amine and dextran aldehyde, affords the delivery of a range of therapeutics to combat cancer, including nucleic acids, small molecules, and antibody drugs.
Journal ArticleDOI
Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells
João Conde,Chenchen Bao,Yeqi Tan,Daxiang Cui,Elazer R. Edelman,Helena S. Azevedo,Hugh J. Byrne,Natalie Artzi,Furong Tian +8 more
TL;DR: The results here suggest that it is likely that the combination of silencing important genes in tumor cells and in their supporting immune cells in the tumor microenvironment, such as TAMs, will greatly improve cancer clinical outcomes.